Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results

Detalhes bibliográficos
Autor(a) principal: Ertan,Elif
Data de Publicação: 2021
Outros Autores: Doğan,Mustafa, Polat,Onur, Efe,Neriman, Akdoğan,Müberra, İnan,Sibel, Duman,Reşat, Duman,Rahmi
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos brasileiros de oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225
Resumo: ABSTRACT Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. Results: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). Conclusion: Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.
id CBO-2_e8df98b5ecbb370cf7b504c22bb5f0c5
oai_identifier_str oai:scielo:S0004-27492021000300225
network_acronym_str CBO-2
network_name_str Arquivos brasileiros de oftalmologia (Online)
repository_id_str
spelling Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month resultsMacular degenerationRanibizumab/therapeutic useAngiogenesis inhibitors/therapeutic useIntravitreal injectionsRetina/pathologyVisual acuityABSTRACT Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. Results: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). Conclusion: Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.Conselho Brasileiro de Oftalmologia2021-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225Arquivos Brasileiros de Oftalmologia v.84 n.3 2021reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20210036info:eu-repo/semantics/openAccessErtan,ElifDoğan,MustafaPolat,OnurEfe,NerimanAkdoğan,Müberraİnan,SibelDuman,ReşatDuman,Rahmieng2021-05-18T00:00:00Zoai:scielo:S0004-27492021000300225Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2021-05-18T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false
dc.title.none.fl_str_mv Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
title Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
spellingShingle Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
Ertan,Elif
Macular degeneration
Ranibizumab/therapeutic use
Angiogenesis inhibitors/therapeutic use
Intravitreal injections
Retina/pathology
Visual acuity
title_short Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
title_full Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
title_fullStr Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
title_full_unstemmed Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
title_sort Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
author Ertan,Elif
author_facet Ertan,Elif
Doğan,Mustafa
Polat,Onur
Efe,Neriman
Akdoğan,Müberra
İnan,Sibel
Duman,Reşat
Duman,Rahmi
author_role author
author2 Doğan,Mustafa
Polat,Onur
Efe,Neriman
Akdoğan,Müberra
İnan,Sibel
Duman,Reşat
Duman,Rahmi
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ertan,Elif
Doğan,Mustafa
Polat,Onur
Efe,Neriman
Akdoğan,Müberra
İnan,Sibel
Duman,Reşat
Duman,Rahmi
dc.subject.por.fl_str_mv Macular degeneration
Ranibizumab/therapeutic use
Angiogenesis inhibitors/therapeutic use
Intravitreal injections
Retina/pathology
Visual acuity
topic Macular degeneration
Ranibizumab/therapeutic use
Angiogenesis inhibitors/therapeutic use
Intravitreal injections
Retina/pathology
Visual acuity
description ABSTRACT Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. Results: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). Conclusion: Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0004-2749.20210036
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Oftalmologia v.84 n.3 2021
reponame:Arquivos brasileiros de oftalmologia (Online)
instname:Conselho Brasileiro de Oftalmologia (CBO)
instacron:CBO
instname_str Conselho Brasileiro de Oftalmologia (CBO)
instacron_str CBO
institution CBO
reponame_str Arquivos brasileiros de oftalmologia (Online)
collection Arquivos brasileiros de oftalmologia (Online)
repository.name.fl_str_mv Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)
repository.mail.fl_str_mv aboonline@cbo.com.br||abo@cbo.com.br
_version_ 1754209031333871616